Home/Pipeline/CHECKvacc

CHECKvacc

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Imugene

About Imugene

Imugene is a clinical-stage biotech with a mission to develop transformative cancer medicines by leveraging a multi-platform strategy focused on immuno-oncology. Its key achievements include advancing a pipeline of seven candidates, most notably the off-the-shelf CAR-T therapy azer-cel and the oncolytic virus platform CF33, with several programs now in Phase 1/2 clinical testing. The company's strategy mitigates risk by pursuing diverse therapeutic modalities and targets, often in combination with standard of care, to address significant unmet needs in oncology. It operates with a capital-efficient model, supported by a world-class scientific advisory board and strategic collaborations.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active